Skip to main content

Novel Rx

    RT @RichardPAConway: Goldman et al. RTX, TCZ in SSc ILD. 129 patients, 87 RTX, 32 TCZ, 10 both. Median changes in %FVC a
    1 year 4 months ago
    Goldman et al. RTX, TCZ in SSc ILD. 129 patients, 87 RTX, 32 TCZ, 10 both. Median changes in %FVC and %DLCO pre-and post-treatment were +0.35% and -0.8% for rituximab and -0.9% and +0.2% for tocilizumab. Majority stable/improved @RheumNow #ACR22 Abstr#1520 https://t.co/ydY5FGEYnQ https://t.co/O9QD7nkjdZ
    RT @RichardPAConway: Avouac @AvouacJerome et al. Maintaining complete B cell depletion assoc RTX efficacy in CTD-ILD. %
    1 year 4 months ago
    Avouac @AvouacJerome et al. Maintaining complete B cell depletion assoc RTX efficacy in CTD-ILD. % with FVC improvement - 67% vs 50% for B cell depletion 1 year, 89% vs 50% B cell depletion last infusion. @RheumNow #ACR22 Abstr#1527 https://t.co/xr7DHOHci2 https://t.co/2n95PgzLxN
    RT @RichardPAConway: Sanchez Martin et al. Assessing effect tocilizumab by PET in GCA. Vascular involvement not generall
    1 year 4 months ago
    Sanchez Martin et al. Assessing effect tocilizumab by PET in GCA. Vascular involvement not generally fully controlled by tocilizumab. Not sure how PET was scored here. @RheumNow #ACR22 Abstr#1257 https://t.co/cGEoScnPb3 https://t.co/W0yYMPMjni
    RT @synovialjoints: Plenary:
    Real-world observational study >1500 pts with IA, 1 year retention infliximab biosimilar
    1 year 4 months ago
    Plenary: Real-world observational study >1500 pts with IA, 1 year retention infliximab biosimilar CT-P13 to GP1111 switch was high. Retention was higher in originator-experienced (92vs83%) & low disease activity Nabi H, DANBIO Abs1112 https://t.co/z84AMUS3GK #ACR22 @RheumNow https://t.co/SgGhd33Esl
    RT @synovialjoints: Plenary:
    Remibrutinib (LOU064) a BTK inhibitor in Sjogren’s
    ◦ Favourable safety profile
    ◦ Well
    1 year 4 months ago
    Plenary: Remibrutinib (LOU064) a BTK inhibitor in Sjogren’s ◦ Favourable safety profile ◦ Well-tolerated over 24 Wks ◦ Improved ESSDAI, salivary flow, Igs ◦ May be first effective oral disease-modifying therapy for SS Dorner T Abs1113 https://t.co/FkgJpwKAJL #ACR22 @RheumNow https://t.co/znxMc27EBI
    RT @doctorRBC: Biologics to treat gut microbiome dysbiosis??
    In axSpA pts treated with bDMARDs for one year, gut microbi
    1 year 4 months ago
    Biologics to treat gut microbiome dysbiosis?? In axSpA pts treated with bDMARDs for one year, gut microbiome resembled those of controls. Collinsella remained stable - possible biomarker? Abs#1162 @RheumNow #ACR22 #ACRBest https://t.co/vmQFJMpNPP
    RT @RichardPAConway: Singh @NamrataRheum et al. 27,421 RA patients, 8225 on b/tsDMARD. b/tsDMARDs did not increase risk
    1 year 4 months ago
    Singh @NamrataRheum et al. 27,421 RA patients, 8225 on b/tsDMARD. b/tsDMARDs did not increase risk of lymphoma. IR 1.68/1000PY (95% CI 1.5-1.9) on csDMARD vs IR 1.73/1000PY (95%CI 1.4-2.1) on b/tsDMARD. @RheumNow #ACR22 Abstr#1210 https://t.co/3Uvz3mvsGM https://t.co/6k3Vqb21KF
    RT @RichardPAConway: Barroso-García et al. ADA vs IFX vs TCZ in severe ocular Behcets with refractory cystoid macular e
    1 year 4 months ago
    Barroso-García et al. ADA vs IFX vs TCZ in severe ocular Behcets with refractory cystoid macular edema. Remission 76% (ADA), 60% (IFX), 67% (TCZ). @RheumNow #ACR22 Abstr#1564 https://t.co/pRVgIdGAGS https://t.co/gOb5wQ9pHv
    RT @uptoTate: BEL after RTX targets IgA2 anti-dsDNA abs and favors formation of anergic/resting B cells while reducing p
    1 year 4 months ago
    BEL after RTX targets IgA2 anti-dsDNA abs and favors formation of anergic/resting B cells while reducing potentially pathogenic B-cell subsets. Abs 0978 #ACR22 @RheumNow https://t.co/Y798OAwtbt https://t.co/IfXOv67MLV